Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | XBP1 | P17861 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 6/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10944032 | 0.91 | TP53 (0.35) | TP53CA2FAAH | |
| SCHEMBL10946946 | 0.91 | TP53 (0.35) | TP53 | |
| SCHEMBL10943832 | 0.88 | CA2 (0.36) | TP53CA2FAAH | |
| SCHEMBL10949491 | 0.88 | CA2 (0.36) | TP53CA2FAAH | |
| SCHEMBL6312594 | 0.81 | TP53 (0.39) | TP53NPC1S1PR2S1PR4ALDH1A1 | |
| SCHEMBL2306255 | 0.76 | CA2 (0.47) | TP53NPC1S1PR2S1PR4ALDH1A1 | |
| SCHEMBL516159 | 0.74 | TP53 (0.39) | TP53OPRM1 | |
| SCHEMBL7515914 | 0.71 | TP53 (0.31) | TP53 | |
| SCHEMBL9193536 | 0.70 | CA2 (0.41) | TP53NPC1S1PR2S1PR4ALDH1A1 | |
| SCHEMBL10944845 | 0.69 | FAAH (0.55) | TP53NPC1S1PR2S1PR4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168638-B2 | Pyrazinecarboxamide derivatives and plant disease controlling agents containing the same | NIHON NOHYAKU CO., LTD. (JP) | 2012-05-01 | — | — | US | disclosed |
| EP-1963286-B1 | PYRAZINECARBOXAMIDE DERIVATIVES AND PLANT DISEASE CONTROLLING AGENTS CONTAINING THE SAME | NIHON NOHYAKU CO LTD (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20090233934-A1 | Pyrazinecarboxamide Derivatives and Plant Disease Controlling Agents Containing the Same | NIHON NOHYAKU CO., LTD. (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1963286-A1 | PYRAZINECARBOXAMIDE DERIVATIVES AND PLANT DISEASE CONTROLLING AGENTS CONTAINING THE SAME | Nihon Nohyaku Co., Ltd. (JP) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007072999-A1 | PYRAZINECARBOXAMIDE DERIVATIVES AND PLANT DISEASE CONTROLLING AGENTS CONTAINING THE SAME | NIHON NOHYAKU CO., LTD (JP) | 2007-06-28 | — | — | WO | disclosed |
| EP-0065730-B1 | 9-THIOMAYTANSINOIDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1986-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233934-A1 | Pyrazinecarboxamide Derivatives and Plant Disease Controlling Agents Containing the Same | CBR3, CNPY2, AADAC | TP53 3722/4885NPC1 1151/4885S1PR2 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.